Neovacs S.A. (EPA:ALNEV)

Market Cap	179.74K -65.4%
Revenue (ttm)	199.27K -75.8%
Net Income	-4.36M
EPS	n/a
Shares Out	159.06K
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,347
Open	1.040
Previous Close	1.130
Day's Range	1.025 - 1.143
52-Week Range	1.015 - 22,000.000
Beta	-1,222.46
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 15, 2026

About Neovacs

Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for autoimmune diseases using its Kinoid technology. The company’s product pipeline includes Kinoid, a therapeutic vaccine which allows the immune system to generate natural polyclonal antibodies. IFNα Kinoid, an anti-interferon alpha vaccine which completed Phase I / IIa and IIb clinical trial for the treatment of lupus erythematosus; and Phase II...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1993
• Employees: 16
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALNEV

Financial Performance

In 2024, Neovacs's revenue was 433,937, a decrease of -18.65% compared to the previous year's 533,412. Losses were -32.91 million, 276.4% more than in 2023.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 14, 2026

Data Sources Report a data error